{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T17:42:40Z","timestamp":1781372560741,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ero.2025.09.007","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T03:41:16Z","timestamp":1760586076000},"page":"319-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Individualised treatment effect prediction: the benefit of initial biological treatment in early rheumatoid arthritis"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7507-5002","authenticated-orcid":false,"given":"Sina","family":"Fadaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Spierings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes W.J.","family":"Bijlsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes W.G.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paco M.J.","family":"Welsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ero.2025.09.007_bib0001","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/annrheumdis-2019-215304","volume":"78","author":"Verhoeven","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ero.2025.09.007_bib0002","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard-2023-224116","article-title":"Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial","volume":"82","author":"\u00d8stergaard","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ero.2025.09.007_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274264","article-title":"Disease activity trajectories for early and established rheumatoid arthritis: real-world data from a rheumatoid arthritis cohort","volume":"17","author":"Movahedi","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ero.2025.09.007_bib0004","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3899\/jrheum.141480","article-title":"Early remission is a realistic target in a majority of patients with DMARD-naive rheumatoid arthritis","volume":"43","author":"Rannio","year":"2016","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2025.09.007_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ero.2025.09.007_bib0006","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ero.2025.09.007_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102308","article-title":"Tapering biologic DMARDs in rheumatoid arthritis","volume":"67","author":"Braverman","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ero.2025.09.007_bib0008","doi-asserted-by":"crossref","first-page":"k4245","DOI":"10.1136\/bmj.k4245","article-title":"Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects","volume":"363","author":"Kent","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ero.2025.09.007_bib0009","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/0962280215623981","article-title":"Identification of predicted individual treatment effects in randomized clinical trials","volume":"27","author":"Lamont","year":"2018","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"10.1016\/j.ero.2025.09.007_bib0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12874-023-01889-6","article-title":"Estimating individualized treatment effects from randomized controlled trials","volume":"23","author":"Rekkas","year":"2023","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"10.1016\/j.ero.2025.09.007_bib0011","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/annrheumdis-2015-207628","article-title":"Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial","volume":"75","author":"Burmester","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"10042","key":"10.1016\/j.ero.2025.09.007_bib0012","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0140-6736(16)30363-4","article-title":"Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial","volume":"388","author":"Bijlsma","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ero.2025.09.007_bib0013","article-title":"Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis?","volume":"2","author":"Ferraccioli","year":"2016","journal-title":"YES. RMD Open."},{"issue":"6","key":"10.1016\/j.ero.2025.09.007_bib0014","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/aje\/kwt312","article-title":"Comparison of random forest and parametric imputation models for imputing missing data using MICE: a CALIBER study","volume":"179","author":"Shah","year":"2014","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ero.2025.09.007_bib0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2288-9-57","article-title":"Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines","volume":"9","author":"Marshall","year":"2009","journal-title":"BMC Med Res Methodol"},{"issue":"26","key":"10.1016\/j.ero.2025.09.007_bib0016","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1002\/sim.9154","article-title":"A tutorial on individualized treatment effect prediction from randomized trials with a binary endpoint","volume":"40","author":"Hoogland","year":"2021","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.ero.2025.09.007_bib0017","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7326\/M18-3667","article-title":"The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement","volume":"172","author":"Kent","year":"2020","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.ero.2025.09.007_bib0018","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/acr.22606","article-title":"Determining the minimally important difference in the Clinical Disease Activity Index for improvement and worsening in early rheumatoid arthritis patients","volume":"67","author":"Curtis","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ero.2025.09.007_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ero.2025.09.007_bib0020","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/j.jpainsymman.2024.06.002","article-title":"Understanding the number needed to treat","volume":"68","author":"Davis","year":"2024","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"10.1016\/j.ero.2025.09.007_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004472","article-title":"On difficulties to define prognostic factors for clinical practice in rheumatoid arthritis","volume":"10","author":"Vittecoq","year":"2024","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.ero.2025.09.007_bib0022","doi-asserted-by":"crossref","first-page":"22279","DOI":"10.3390\/ijms151222279","article-title":"Smoking and rheumatoid arthritis","volume":"15","author":"Chang","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.ero.2025.09.007_bib0023","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300041","article-title":"Vaduganathan M. Individualized treatment effect prediction with machine learning\u2014salient considerations","volume":"3","author":"Desai","year":"2024","journal-title":"NEJM Evid"},{"issue":"1","key":"10.1016\/j.ero.2025.09.007_bib0024","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/biostatistics\/kxy028","article-title":"Individualized treatment effects with censored data via fully nonparametric Bayesian accelerated failure time models","volume":"21","author":"Henderson","year":"2020","journal-title":"Biostatistics"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125000795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125000795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T21:12:12Z","timestamp":1766005932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708125000795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S3050708125000795"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2025.09.007","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualised treatment effect prediction: the benefit of initial biological treatment in early rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2025.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}